miR-144-3p inhibited the growth, metastasis and epithelial-mesenchymal transition of colorectal adenocarcinoma by targeting ZEB1/2

Taiyuan Li¹², Cheng Tang¹*, Zhixiang Huang¹*, Lingling Yang³*, Hua Dai⁴, Bo Tang¹, Benping Xiao⁵, Jianfeng Li¹, Xiong Lei¹,²,*

¹Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China
²Gastrointestinal Surgical Institute, Nanchang University, Nanchang 330006, Jiangxi, China
³Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China
⁴Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China
⁵Department of General Surgery, Jiangxi Pingxiang People’s Hospital, Pingxiang 337000, Jiangxi, China
*Equal contribution

Correspondence to: Xiong Lei; email: leixionglingt@126.com, https://orcid.org/0000-0002-4055-3414

Keywords: colorectal cancer, miR-144-3p, epithelial-mesenchymal transition, metastasis, ZEB1/2

Received: November 23, 2020 Accepted: June 4, 2021 Published: July 5, 2021

Copyright: © 2021 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

miR-144-3p is aberrantly expressed in several types of human cancer and functions as a tumor suppressor by inhibiting metastasis. However, the clinical significance and biological function of miR-144-3p in colorectal adenocarcinoma (CRA) have yet to be elucidated. Here we reported that miR-144-3p expression level was significantly down-regulated in CRA tissues compared with matched noncancerous colorectal mucosa tissues. Low miR-144-3p expression was correlated with adverse clinicopathologic characteristics and poor prognosis of CRA patients. Cox regression analysis showed that low miR-144-3p expression was an independent risk factor for DFS and OS in CRA. In vitro and in vivo assays showed that miR-144-3p significantly inhibited proliferation, migration and invasion of CRA cells. In particular, miR-144-3p could suppress EMT process of CRA cells by regulating the cytoskeleton and EMT markers. Bioinformatics analysis indicated that EMT associated transcription factors ZEB1 and ZEB2 were potential targets of miR-144-3p, and miR-144-3p inhibited ZEB1 and ZEB2 expression and was negatively correlated with their expression in CRA. Finally, we confirmed that ZEB1 and ZEB2 down-regulation collaboratively mediated the inhibitory effect of miR-144-3p on proliferation, invasion and EMT of CRA cells. In conclusion, our study provided evidence that miR-144-3p could inhibit CRA cell proliferation, invasion and EMT by targeting ZEB1/2.

INTRODUCTION

Colorectal cancer (CRC) has become the second leading cause of cancer related death, accounting for about 1 in 10 cancer death [1]. About 98% of CRC histopathologic type is colorectal adenocarcinoma (CRA) [2]. Despite improved survival rate of CRA patients due to the development of chemotherapeutic treatments and surgical technology, about 30% CRA patients present with metastasis at the time of diagnosis, which is the major obstacle to improving the prognosis of CRA patients [3]. The liver is the major organ for CRA metastasis, and liver metastasis would develop in about 15% of operable CRA patients and over 50% of inoperable CRA patients [4].
Tumor metastasis involves complex cascade, which is regulated by molecular mechanisms [5]. Therefore, understanding the molecular mechanisms of CRA metastasis cascade will help develop new targeted drugs and improve the survival rate of CRA patients.

Epithelial-mesenchymal transition (EMT) occurs in embryonic developmental stages (e.g. gastrointestinal and neuronal crest formation) and pathological or physiological processes (e.g. wound healing or fibrosis). EMT is often aberrantly activated in tumor cells to gain invasive ability for metastasis [6, 7]. The activation of EMT involves many intracellular signaling pathways that repress E-cadherin expression while up-regulate vimentin expression [8]. EMT associated transcriptional factors, such as SNAI, ZEB and TWIST, are aberrantly upregulated during EMT and participate in CRA metastasis [9]. Accumulating studies demonstrated that miRNAs modulate CRA metastasis via regulating EMT [10, 11].

miRNAs regulate gene expression by preventing translation or promoting mRNA degradation [12]. Alterations in miRNA expression profiles are related to the staging and prognosis of carcinomas [13–15] Recent evidence showed that miR-144-3p may be a tumor suppressor [16–18]. In particular, miR-144-3p inhibited EMT process and cancer metastasis [18–20]. In addition, plasma miR-144-3p level was significantly lower in CRA patients than in healthy controls [21]. However, the significance of miR-144-3p in CRA remains unclear.

In this study, we investigated the expression profile and clinical significance of miR-144-3p in CRA patients and explored molecular mechanisms of miR-144-3p in CRA.

MATERIALS AND METHODS

Colorectal adenocarcinoma samples

Fresh frozen colorectal adenocarcinoma tissues (CRAT) and corresponding noncancerous colorectal mucosal tissues (NCMT) harvested from 160 CRA patients at the First Affiliated Hospital of Nanchang University from January 2009 to December 2011 were set as training cohort. In addition, matched NCMTs, CRATs, liver metastatic nodule (LMNs) were obtained from 8 patients with liver-only metastases. Another 140 matched fresh frozen CRATs and NCMTs from CRA patients undergoing radical resection between July 2011 and July 2013 at People's Hospital of Pingxiang were set as validation cohort. None of CRA patients had chemotherapy or radiotherapy before the surgery. This study was approved by Ethics Committee of First Affiliated Hospital of Nanchang University. All participants provided informed consent.

Follow-up study

Overall survival (OS) indicated the time from the surgery to tumor related death or the last follow-up if the patients survived [2]. Disease-free survival (DFS) indicated the time from the surgery till the patient survived without recurrence or metastasis [2]. All follow-up data were collected for further analysis.

Cell culture and transfection

Cancer cell lines HCT116, LoVo, SW480, HT-29, SW620 and colorectal mucosal cell line FHC were provided by American Type Culture Collection. Cell were cultured and cell transfection was performed with miR-144-3p mimic, inhibitor and their corresponding control sequences (RiboBio, Guangzhou, China) by using Lipofectamine (Invitrogen, Carlsbad, CA, USA).

PCR

Total RNA was extracted by using TRIzol (Invitrogen) and cDNA was synthesized by using cDNA kit (Toyobo, Japan). PCR analysis was performed by using SYBR Green Master kit (Toyobo) (details in Supplementary Materials).

Western blot analysis

Total proteins were extracted by using RIPA buffer (Beyotime Institute of Biotechnology, Jiangsu, China), and the details for Western blotting were shown in Supplementary Materials.

Immunohistochemistry (IHC)

The tissue sections were dewaxed, rehydrated, blocked, and then incubated with primary antibodies and horseradish peroxidase conjugated secondary antibody, sequentially (Zhongshan Goldenbridge Biotech, Beijing, China). The sections were then stained with 3,3′-diaminobenzidine substrate.

Cell proliferation assay

The proliferation ability of CRA cells was analyzed by methyl thiazolyl tetrazolium (MTT), EdU proliferation and colony formation analysis (details in Supplementary Materials).

Transwell and cell adhesion assays

Cell motility and invasive ability and cell adhesion were examined by transwell migration and invasion assay, cell-cell adhesion and cell-extracellular matrix (ECM) assay, respectively (details in Supplementary Materials).
Immunofluorescence (IF) and flow cytometry

The details of IF staining and flow cytometry of vimentin and E-cadherin were described in Supplementary Materials. Briefly, cells were fixed and incubated with rhodamine conjugated phalloidin (Solarbio, Beijing, China). The nuclei were stained with DAPI and cells were observed under fluorescence microscope (Nikon Corporation, Japan).

Animal experiments

CRA cells (5 x 10⁶) were subcutaneously injected into left upper flank of nude male BALB/c mice (4-5 weeks old). Tumor volume was calculated with formula: tumor volume (cm³) = (long axis x short axis²)/2 [22]. After 6 weeks, tumor tissues were dissected. For in vivo metastatic assay, the spleen was exposed after anesthesia and the incision on left lateral flank in nude mice. One month after intrasplenic injection of 1x10⁶ CRA cells, the mice were euthanized and liver specimens were collected to examine metastatic nodules.

Statistical analysis

All data were analyzed with software SPSS 18 (SPSS, Chicago, IL, USA). The differences between two groups were analyzed by t test or χ² test. Survival curve was calculated by Kaplan-Meier method. Factors associated with OS and DFS were identified by Cox proportional hazard regression analysis. P < 0.05 indicated significance.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the Institutional Review Boards of the First Affiliated Hospital of Nanchang University and Jiangxi Pingxiang People's Hospital, and was performed in accordance with the Declaration of Helsinki and current ethical guidelines. Prior informed consent was obtained from all participants.

Consent for publication

Patients provided written informed consent for publication. All authors have read and approved of publication of this manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are openly available.

RESULTS

miR-144-3p was significantly downregulated in CRA

The analysis of 160 pairs of fresh frozen CRATs and corresponding NCMTs from training cohort showed that miR-144-3p level was lower in CRATs than in NCMTs (Figure 1A). Furthermore, miR-144-3p level was lower in CRATs with TNM stage III than in those with TNM stage I/II (Figure 1B). Moreover, analysis of 8 matched NCMTs, CRATs and LMNs demonstrated that miR-144-3p level gradually decreased from NCMTs, CRATs to LMNs (Figure 1C). Analysis of miR-144-3p level in CRATs and LMNs from the GEO dataset (GSE44121) showed that miR-144-3p level was lower in LMNs than in CRATs (Figure 1D).

Low miR-144-3p expression was associated with poor prognosis of CRA

Next we explored clinical significance of miR-144-3p in CRA following ReMARK guidelines for prognostic tumor biomarkers [23]. We found that miR-144-3p level was significantly lower in CRATs than in NCMTs (data not shown). According to relative miR-144-3p level in CRATs, CRA patients were further divided into low miR-144-3p expression group (log₂ fold change of CRAT/NCMT ≤ −1) and high miR-144-3p expression group (log₂ fold change of CRAT/NCMT > −1). First, we found no differences in clinicopathologic characteristics for CRA patients between training cohort and validation cohort (Table 1). In training cohort, miR-144-3p level was related to adverse clinicopathological features such as tumor size (P=0.002), pN stage (P=0.002), pT stage (P=0.003), distant metastasis (P=0.004) and lymphatic/microvascular/nerve invasion (P=0.001) (Table 2). Similarly, in validation cohort, miR-144-3p level was related to tumor differentiation (P=0.011), pT stage (P=0.003), pN stage (P=0.027), tumor size (P=0.001), distant metastasis (P=0.018) and lymphatic/microvascular/nerve invasion (P<0.001) (Table 3). Based on follow-up data, CRA patients in training cohort with low miR-144-3p level showed shorter OS (P=0.006) and shorter DFS (P=0.002) compared to patients with high miR-144-3p level (Figure 1E, 1F). CRA patients in validation cohort with low miR-144-3p level showed shorter OS (P=0.007) and DFS (P=0.009) compared to patients with high miR-144-3p level (Figure 1G, 1H). Furthermore, Cox proportional hazards regression model identified low miR-144-3p level as a risk factor for both OS and DFS (Tables 3, 4).

miR-144-3p inhibited CRA cell proliferation

Next we explored biological function of miR-144-3p in CRAPCR analysis of miR-144-3p expression in
CRA cell lines and colorectal mucosal cell line FHC showed lower expression of miR-144-3p in CRA cell lines than in FHC cell line (Figure 2A). In particular, HCT116 had the highest and Lovo had the lowest level of miR-144-3p, and they were selected for subsequent assays. Transfection of miR-144-3p mimic effectively increased miR-144-3p level in Lovo cells and transfection of miR-144-3p inhibitor reduced miR-144-3p level in HCT116 cells (Figure 2B).

MTT assay showed that miR-144-3p mimic inhibited Lovo cell proliferation, while miR-144-3p inhibitor significantly promoted HCT116 cell proliferation (Figure 2C). Moreover, miR-144-3p mimic significantly
Table 1. Clinicopathologic characteristics of patients with CRA in the training cohort and validation cohort.

| Clinicopathologic parameters | Training cohort | Validation cohort | P  |
|------------------------------|----------------|------------------|----|
| **Gender**                   |                |                  |    |
| Female                       | 62             | 58               |    |
| Male                         | 98             | 82               | 0.639 |
| **Age (y)**                  |                |                  |    |
| ≤60                          | 71             | 60               |    |
| >60                          | 89             | 80               | 0.816 |
| **CEA (ng/ml)**              |                |                  |    |
| ≤5                           | 68             | 65               |    |
| >5                           | 92             | 75               | 0.560 |
| **Tumor differentiation**    |                |                  |    |
| I/II                         | 75             | 62               |    |
| III/IV                       | 85             | 78               | 0.728 |
| **Tumor site**               |                |                  |    |
| Colon                        | 58             | 54               |    |
| Rectum                       | 102            | 86               | 0.720 |
| **Tumor size**               |                |                  |    |
| ≤5 cm                        | 105            | 93               |    |
| >5 cm                        | 55             | 47               | 0.903 |
| **pT stage**                 |                |                  |    |
| T1/T2                        | 52             | 51               |    |
| T3/T4                        | 108            | 89               | 0.542 |
| **pN stage**                 |                |                  |    |
| N0                           | 72             | 66               |    |
| N+                           | 88             | 74               | 0.729 |
| **Lymphatic/microvascular/nerve invasion** | | | |
| Negative                     | 66             | 55               |    |
| Positive                     | 94             | 85               | 0.814 |
| **Distant metastasis**       |                |                  |    |
| Negative                     | 76             | 72               |    |
| Positive                     | 84             | 68               | 0.563 |

* detected during the follow-up period.

inhibited colony formation of Lovo cells, while miR-144-3p inhibitor significantly enhanced colony formation of HCT116 cells (Figure 2D). Edu assay showed that miR-144-3p mimic reduced Lovo cell proliferation and miR-144-3p inhibitor increased HCT116 cell proliferation (Figure 2E). By using subcutaneous xenograft tumor model, we found that tumors derived from Lovo cells treated with miR-144-3p mimic were significantly smaller (Figure 2F). In contrast, miR-144-3p inhibitor promoted the growth of tumors derived from HCT116 cells (Figure 2F).

**miR-144-3p inhibited CRA metastasis**

Transwell migration assays showed that miR-144-3p mimic significantly inhibited Lovo cell migration, while miR-144-3p downregulation in HCT116 significantly increased cell migration (Figure 3A). Transwell invasion assays showed similar results (Figure 3B). Adhesion assays showed that miR-144-3p mimic significantly enhanced cell-cell adhesion but decreased cell-ECM adhesion in Lovo cells. However, miR-144-3p inhibitor significantly decreased cell-cell adhesion but increased cell-ECM adhesion in HCT116 cells (Figure 3C, 3D). Furthermore, we found lower number of liver metastatic nodules from mice with the injection of Lovo cells transfected with miR-144-3p mimic and higher number of liver metastatic nodules from mice with the injection of HCT116 cells transfected with miR-144-3p inhibitor, compared to control mice (Figure 3E).
Table 2. Correlations between expression of miR-144-3p and clinicopathologic parameters of CRA patients in the training and validation cohort.

| Clinicopathologic parameters                | Training cohort | Validation cohort |
|---------------------------------------------|-----------------|-------------------|
|                                             | n   | miR-144-3p expression | P    | n   | miR-144-3p expression | P    |
|                                             |     | Low | High |     | Low | High          |      |
| Gender                                      |     |     |      |     |     |                |      |
| Female                                      | 62  | 40  | 22   |     | 58  | 27  | 31 |     | 82  | 49  | 33  | 0.168 |
| Male                                        | 98  | 55  | 43   | 0.324 | 82  | 49  | 33  | 0.168 |
| Age (y)                                     |     |     |      |     |     |                |      |
| ≤60                                         | 71  | 46  | 25   |     | 60  | 31  | 29 |     | 80  | 45  | 35  | 0.611 |
| >60                                         | 89  | 49  | 40   | 0.257 | 80  | 45  | 35  | 0.611 |
| CEA (ng/ml)                                 |     |     |      |     |     |                |      |
| ≤5                                          | 68  | 35  | 33   |     | 65  | 31  | 34 |     | 75  | 45  | 30  | 0.175 |
| >5                                          | 92  | 60  | 32   | 0.103 | 82  | 49  | 33  | 0.168 |
| Tumor differentiation                       |     |     |      |     |     |                |      |
| I/II                                        | 75  | 39  | 36   |     | 62  | 26  | 36 |     | 78  | 50  | 28  | 0.011 |
| III/IV                                      | 85  | 56  | 29   | 0.079 | 86  | 42  | 44  | 0.119 |
| Tumor site                                  |     |     |      |     |     |                |      |
| Colon                                       | 58  | 31  | 27   |     | 54  | 34  | 20 |     | 72  | 32  | 40  | 0.002 |
| Rectum                                      | 102 | 64  | 38   | 0.315 | 86  | 42  | 44  | 0.119 |
| Tumor size                                  |     |     |      |     |     |                |      |
| ≤5 cm                                       | 105 | 53  | 52   |     | 93  | 41  | 52 |     | 74  | 47  | 27  | 0.027 |
| >5 cm                                       | 55  | 42  | 13   | 0.002 | 47  | 35  | 12  | 0.001 |
| pT stage                                    |     |     |      |     |     |                |      |
| T1/T2                                       | 52  | 22  | 30   |     | 51  | 19  | 32 |     | 89  | 57  | 32  | 0.003 |
| T3/T4                                       | 108 | 73  | 35   | 0.003 | 89  | 57  | 32  | 0.003 |
| pN stage                                    |     |     |      |     |     |                |      |
| N0                                          | 72  | 33  | 39   |     | 66  | 29  | 37 |     | 74  | 47  | 27  | 0.027 |
| N+                                          | 88  | 62  | 26   | 0.002 | 74  | 47  | 27  | 0.027 |
| Lymphatic/microvascular/nerve invasion      |     |     |      |     |     |                |      |
| Negative                                    | 66  | 29  | 37   |     | 55  | 18  | 37 |     | 85  | 58  | 27  | <0.001 |
| Positive                                    | 94  | 66  | 28   | 0.001 | 85  | 58  | 27  | <0.001 |
| Distant metastasis                          |     |     |      |     |     |                |      |
| Negative                                    | 76  | 36  | 40   |     | 72  | 32  | 40 |     | 72  | 32  | 40  | 0.018 |
| Positive                                    | 84  | 59  | 25   | 0.004 | 68  | 44  | 24  | 0.018 |

miR-144-3p inhibited EMT

Next, we wondered whether miR-144-3p inhibited CRA metastasis by suppressing EMT. We detected actin cytoskeleton of CRA cells based on F-actin staining, because actin transformation is involved in cell adhesion and migration and EMT [24, 25]. Compared to control cells, Lovo cells treated with miR-144-3p mimic showed a cobblestone shape and shrunk F-actin fiber (Figure 4A). In contrast, HCT116 cells treated with miR-144-3p inhibitor presented elongated shape and long F-actin fibers (Figure 4A). Moreover, miR-144-3p mimic promoted E-cadherin expression but inhibited vimentin expression. Inversely, miR-144-3p inhibitor inhibited E-cadherin expression while enhanced vimentin expression (Figure 4B, 4C). Immunofluorescence staining for vimentin and E-cadherin showed similar results (Figure 4D). Flow cytometry showed higher E-cadherin expression and lower vimentin expression in Lovo cells treated with miR-144-3p mimic, while opposite results were shown in HCT116 cells treated with miR-144-3p inhibitor (Figure 4E).
Table 3. Cox proportional hazard regression analysis for OS in the training and validation cohort.

| Parameters                        | Training cohort | Validation cohort |
|-----------------------------------|-----------------|------------------|
|                                   | Univariate      | Multivariate     | HR (95% CI) | p    | HR (95% CI) | p    |
|                                   | analysis        | analysis         |             |      |             |      |
| Gender (male vs female)           | 0.819           | 0.470            | NA          |      | 1.183       | 0.583 |
| (0.476–1.409)                     |                 |                  |             |      | (0.650–2.153) |      |
| Age (y, >60 vs ≤60)               | 1.020           | 0.942            | NA          |      | 1.497       | 0.230 |
| (0.593–1.756)                     |                 |                  |             |      | (0.774–2.893) |      |
| CEA (ng/ml)                       | 1.785           | 0.053            | NA          |      | 1.490       | 0.188 |
| (ng/ml, >5 vs ≤5)                 |                 |                  |             |      | (0.823–2.696) |      |
| Tumor differentiation (III/IV vs II) | 1.395           | 0.011            | 1.432       | 0.251| 2.467       | 0.003 |
| (1.081–1.800)                     |                 | (0.776–2.643)    |             |      | (1.357–4.485) | 0.079|
| Tumor site (Colon vs Rectum)      | 1.194           | 0.563            | NA          |      | 1.412       | 0.244 |
| (0.656–2.174)                     |                 |                  |             |      | (0.790–2.522) |      |
| Tumor size (cm, >5 vs ≤5)         | 1.302           | 0.025            | 2.336       | 0.010| 1.934       | 0.046 |
| (1.033–1.640)                     |                 | (1.229–4.439)    |             |      | (1.012–3.699) | 0.117|
| pT stage (T3/T4 vs T1/T2)         | 1.849           | 0.004            | 1.686       | 0.002| 2.317       | 0.013 |
| (1.214–2.818)                     |                 | (1.213–2.343)    |             |      | (1.194–4.498) | 0.005|
| pN stage (N0 vs N+)               | 2.172           | <0.001           | 1.901       | 0.003| 2.311       | 0.008 |
| (1.424–3.314)                     |                 | (1.241–2.913)    |             |      | (1.242–4.302) | 0.014|
| Lymphatic/microvascular/nerve      | 2.144           | 0.010            | 2.318       | 0.035| 2.132       | 0.011 |
| invasion (Positive vs Negative)   | (1.196–3.844)   | (1.059–5.076)    |             |      | (1.188–3.825) | 0.022|
| miR-144-3p expression (High vs Low)| 0.437           | 0.006            | 0.471       | 0.017| 0.443       | 0.007 |
| (0.237–0.806)                     |                 | (0.254–0.874)    |             |      | (0.241–0.814) | 0.027|

Table 4. Cox proportional hazard regression analysis for DFS in the training and validation cohort.

| Parameters                        | Training cohort | Validation cohort |
|-----------------------------------|-----------------|------------------|
|                                   | Univariate      | Multivariate     | HR (95% CI) | p    | HR (95% CI) | p    |
|                                   | analysis        | analysis         |             |      |             |      |
| Gender (male vs female)           | 0.728           | 0.177            | NA          |      | 1.230       | 0.459 |
| (0.459–1.154)                     |                 |                  |             |      | (0.712–2.126) |      |
| Age (y, >60 vs ≤60)               | 1.138           | 0.588            | NA          |      | 1.661       | 0.113 |
| (0.714–1.814)                     |                 |                  |             |      | (0.888–3.107) |      |
| CEA (ng/ml)                       | 1.582           | 0.063            | NA          |      | 1.625       | 0.087 |
| (ng/ml, >5 vs ≤5)                 |                 |                  |             |      | (0.932–2.836) |      |
| Tumor differentiation (III/IV vs II) | 1.288           | 0.035            | 1.493 (0.844–2.641) | 0.169| 2.636       | 0.001 |
| (1.018–1.630)                     |                 | (1.059–5.076)    |             |      | (1.484–4.682) | 0.089|
| Tumor site (Colon vs Rectum)      | 1.097           | 0.747            | NA          |      | 1.089       | 0.760 |
| (0.625–1.924)                     |                 |                  |             |      | (0.631–1.880) |      |
| Tumor size (cm, >5 vs ≤5)         | 1.304           | 0.019            | 1.489 (0.771–2.873) | 0.236| 1.826       | 0.047 |
| (1.044–1.629)                     |                 | (1.009–3.306)    |             |      | (0.849–2.901) | 0.151|
| pT stage (T3/T4 vs T1/T2)         | 1.765           | 0.005            | 1.593 (1.196–2.121) | 0.001| 1.954       | 0.026 |
| (1.187–2.625)                     |                 | (1.082–3.529)    |             |      | (1.064–3.642) | 0.031|
| pN stage (N0 vs N+)               | 2.027           | <0.001           | 2.271 (1.260–4.092) | 0.006| 2.217       | 0.002 |
| (1.363–3.014)                     |                 | (1.222–4.022)    |             |      | (1.499–4.643) | 0.001|
| Lymphatic/microvascular/nerve      | 2.241           | 0.004            | 2.408 (1.169–4.961) | 0.017| 2.303       | 0.003 |
| invasion (Positive vs Negative)   | (1.297–3.874)   | (1.326–3.999)    |             |      | (1.174–4.007) | 0.013|
| miR-144-3p expression (High vs Low)| 0.451           | 0.002            | 0.467 (0.276–0.789) | 0.004| 0.496       | 0.009 |
| (0.269–0.754)                     |                 | (0.289–0.852)    |             |      | (0.265–0.896) | 0.021|
Figure 2. miR-144-3p was downregulated in CRA cell lines and inhibited CRA cell proliferation and growth. (A) miR-144-3p expression was downregulated in CRA cell lines HCT116, Lovo, SW480, SW620, HT-29 compared to normal colorectal mucosal cell line FHC. (B) qRT-PCR was performed to verify the efficiency of overexpression in Lovo cells transfected with miR-144-3p mimic and knockdown in HCT116 cells transfected with miR-144-3p inhibitor. (C) MTT assay of Lovo and HCT116 cell proliferation. (D) Colony formation assay of Lovo and HCT116 cells. (E) Edu assay of the proliferation ability of Lovo cells transfected with miR-144-3p mimic and HCT116 cells transfected with miR-144-3p inhibitor. (F) The growth curve showed the change of the volume of subcutaneous tumors from indicated CRA cells and the representative images of subcutaneous tumors harvested 6 weeks after CRA cell inoculation in the right panel. Scale bar: 1cm. NC, normal control. **, P<0.01; ***, P<0.001.
Figure 3. miR-144-3p inhibited CRA cell migration, invasion and tumor metastasis. (A) Transwell migration assay of migratory ability of Lovo cells transfected with miR-144-3p mimic and HCT116 cells transfected with miR-144-3p inhibitor. (B) Transwell invasion assay of invasive ability of Lovo cells transfected with miR-144-3p mimic and HCT116 cells transfected with miR-144-3p inhibitor. (C) Overexpression of miR-144-3p in Lovo cells significantly enhanced cell-cell adhesion and decreased cell-ECM adhesion. (D) Knockdown of miR-144-3p in HCT116 cells significantly inhibited cell-cell adhesion and increased the cell-ECM adhesion. (E) In vivo metastatic assays by splenic injection showed that miR-144-3p inhibited CRA liver metastasis. The number of liver metastatic nodules from mice with inoculation of Lovo^{miR-144-3p mimic} cells was significantly smaller than that from mice with inoculation of control cells, whereas the number of liver metastatic nodules from mice with inoculation of HCT116^{miR-144-3p inhibitor} cells was significantly larger than that from mice with inoculation of control cells. ECM, extracellular matrix. *, P<0.05; **, P<0.01; ***, P<0.001.
Figure 4. miR-144-3p inhibited EMT process of CRA cells. (A) Representative images of cytoskeleton showed that miR-144-3p affected polymerization of F-actin and cellular morphology of CRA cells. (B) qRT-PCR analysis of the expression level of epithelial marker E-cadherin and mesenchymal marker vimentin in CRA cells. (C) Western blot analysis of the expression level of E-cadherin and vimentin in CRA cells. (D) Representative IF images showed the expression of E-cadherin and vimentin in CRA cells. (E) Flow cytometry analysis of E-cadherin and Vimentin in CRA cells. The results showed that E-cadherin expression was enriched and vimentin expression was reduced in Lovo cells treated with miR-144-3p mimic, while opposite results were observed in HCT116 cells treated with miR-144-3p inhibitor. ***, P < 0.001.
ZEB1 and ZEB2 are direct targets of miR-144-3p

Next we attempted to identify the targets of miR-144-3p, and searched four databases, including TargetScan [26], miRDB [27], miRTarBase [28] and miRDIP, [29]. Among 78 genes predicted by all four databases, we focused on EMT key transcription factors ZEB1, ZEB2 [30, 31]. (Figure 5A). We constructed wild type (WT) luciferase reporter containing 3’-UTR of ZEB1/ZEB2 and mutant type (Mut) luciferase reporter containing mutant binding sequences of ZEB1/ZEB2 for miR-144-3p (Figure 5B). The results of luciferase reporter assay showed that miR-144-3p inhibited luciferase activity of ZEB1 and ZEB2 3’-UTR, but not that of mutant ZEB1 and ZEB2 3’-UTR (Figure 5C). qRT-PCR and Western blot analysis showed that miR-144-3p mimic significantly decreased ZEB1 and ZEB2 expression in Lovo cells while miR-144-3p inhibitor increased ZEB1 and ZEB2 expression in HCT116 cells (Figure 5D, 5E). Furthermore, miR-144-3p level showed negative correlation with ZEB1/2 levels in CRATs (Figure 5F).

ZEB forms a mutually inhibitory feedback loop with transcription factors OVOL1/2 [32] Therefore, we examined the expression of transcription factors OVOL1/2. While miR-144-3p mimic induced the expression of OVOL1/2 in Lovo cells, miR-144-3p inhibitor suppressed OVOL1/2 expression in HCT116 cells (Figure 5G, 5H).

ZEB1 and ZEB2 abrogated the inhibition of CRA cell proliferation and invasion by miR-144-3p

Next, we upregulated ZEB1/2 expression in Lovo 3p mimic cells and downregulated ZEB1/2 expression in HCT116 inhibitor cells (Figure 6A, 6B). MTT assay showed that restoration of ZEB1 or ZEB2 could partly recover the proliferation of Lovo 3p mimic cells (Figure 6C). However, when both ZEB1 and ZEB2 were elevated, the proliferation of Lovo 3p mimic cells was completely restored (Figure 6C). In HCT116 inhibitor cells, knockdown of ZEB1 or ZEB2 could partly inhibit enhanced proliferation, which could be fully suppressed by knockdown of both ZEB1 and ZEB2 (Figure 6D). Similarly, the restoration of ZEB1 or ZEB2 alone could partly recover the migration and invasion of Lovo 3p mimic cells (Figure 6D). The migration and invasion of Lovo 3p mimic cells were completely restored after the overexpression of both ZEB1 and ZEB2 (Figure 6E). In HCT116 inhibitor cells, knockdown of ZEB1 or ZEB2 could partly inhibit enhanced migration and invasion (Figure 6F), whereas knockdown of both ZEB1 and ZEB2 completely suppressed cell migration and invasion (Figure 6F).

ZEB1 and ZEB2 mediated the inhibition of EMT by miR-144-3p

Finally, we examined whether miR-144-3p may inhibit EMT of CRA cells by targeting ZEB1 and ZEB2. In Lovo 3p mimic cells, the upregulation of ZEB1 or ZEB2 alone could partly upregulate vimentin expression and partly inhibit E-cadherin expression (Figure 7A, 7B). When both ZEB1 and ZEB2 were upregulated, vimentin expression increased while E-cadherin expression decreased significantly (Figure 7A, 7B). In HCT116 inhibitor, knockdown of ZEB1 or ZEB2 alone could partly downregulate vimentin expression and upregulate E-cadherin expression, but the effects were better after knockdown of both ZEB1 and ZEB2 (Figure 7A, 7B). Immunofluorescence and flow cytometry confirmed that ZEB1 and ZEB2 mediated the effect of miR-144-3p on EMT in CRA cells (Figure 7C, 7D).

Next we performed IHC to detect E-cadherin, vimentin, ZEB1 and ZEB2 in serial sections of NCMT and CRAT with high or low miR-144-3p expression level, and found that NCMT and CRAT with high miR-144-3p level had low levels of ZEB1, ZEB2 and vimentin and high level of E-cadherin, while CRAT with low miR-144-3p level exhibited opposite levels of these proteins (Figure 7E).

DISCUSSION

This study showed that miR-144-3p level in CRATs was lower compared to matched NCMTs, and was lower in CRATs with advanced TNM stage than in CRATs with early TNM stage. In addition, miR-144-3p level progressively decreased from matched NCMTs, CRATs to LMNs. These results suggest that miR-144-3p may modulate CRA metastasis.

miRNA expression level has been wildly utilized to assess tumor pathological stages and clinical prognosis [33–35]. In this study, miR-144-3p level in CRA was significantly correlated to aggressive clinicopathological features and poor OS and DFS. In addition, low miR-144-3p level was a risk factor for OS and DFS in CRA. Therefore, miR-144-3p can be a prognostic biomarker for CRA patients after radical surgery.

Studies have shown that miR-144-3p could inhibit tumor proliferation, invasion and metastasis [36–38]. However, its biological function in CRA remains unclear. We demonstrated that miR-144-3p inhibited CRA cell proliferation, invasion and metastasis, indicating its pivotal role in CRA progression. miRNAs play critical role in regulating EMT during CRA development [39]. miR-144-3p could inhibit EMT and
Figure 5. ZEB1 and ZEB2 were direct targets of miR-144-3p. (A) Venn diagram showed direct targets of miR-144-3p in four public database and crucial EMT-TFs for CRA. Only two potential targets ZEB1 and ZEB2 were presented in all the four database and EMT-TFs. (B) The predicted sequences of miR-144-3p binding sites within the 3'-UTR of ZEB1 and ZEB2 including the wild-type (WT) or mutant (Mut) binding site were shown. (C) Luciferase reporter assay showed that overexpression of miR-144-3p significantly repressed luciferase activity in 293T cells transfected with WT binding site of ZEB1 and ZEB2 3'-UTR. (D&E) miR-144-3p inhibited ZEB1 and ZEB2 expression. (D) qRT-PCR results showed mRNA expression levels of ZEB1 and ZEB2 in Lovo miR-144-3p mimic cells, HCT116 cells miR-144-3p inhibitor and matched control cells. Data were analyzed by using 2^{-ΔΔCt} method. (E) Western blot results showed protein expression of ZEB1 and ZEB2 in Lovo miR-144-3p mimic cells, HCT116 cells miR-144-3p inhibitor and matched control cells. (F) qRT-PCR analysis of ZEB1 and ZEB2 mRNA expression level in 30 CRAs. Pearson correlation analysis was applied to examine the correlation between miR-144-3p expression and ZEB1 or ZEB2 mRNA expression. (G, H) miR-144-3p promoted OVOL1/2 expression. (G) Western blot analysis of protein expression of transcription factors OVOL1/2. miR-144-3p mimic induced the expression of OVOL1/2 in Lovo cells and miR-144-3p inhibitor reduced OVOL1/2 expression in HCT116 cells. (H) miR-144-3p mimic induced mRNA expression of OVOL1/2 in Lovo cells and miR-144-3p inhibitor reduced OVOL1/2 expression in HCT116 cells. TF, transcription factor. *** P < 0.001.
Figure 6. ZEB1 and ZEB2 collaboratively abrogated the inhibitory effect of miR-144-3p on CRA cell proliferation and invasion. (A) qRT-PCR analysis of ZEB1, ZEB2 expression in Lovo \textsuperscript{miR-144-3p mimic} cells with overexpression of ZEB1 or/and ZEB2 and in HCT116 \textsuperscript{miR-144-3p inhibitor} cells with knockdown of ZEB1 or/and ZEB2. (B) Western blot analysis of protein expression of ZEB1 and ZEB2 in indicated cells. (C) MTT assay of proliferation ability of Lovo \textsuperscript{miR-144-3p mimic} cells. (D) MTT assay of proliferation ability of HCT116 \textsuperscript{miR-144-3p inhibitor} cells. (E) Transwell migration and invasion assays of the migration and invasion of Lovo \textsuperscript{miR-144-3p mimic} cells. (F) Transwell migration and invasion assay of HCT116 \textsuperscript{miR-144-3p inhibitor} cells after knockdown of ZEB1 or/and ZEB2. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 7. ZEB1 and ZEB2 collaboratively mediated the effect of miR-144-3p on CRA cell EMT. (A) qRT-PCR analysis of E-cadherin and vimentin expression in Lovo\textsuperscript{miR-144-3p mimic} cells with overexpression of ZEB1 or/and ZEB2, and in HCT116\textsuperscript{miR-144-3p inhibitor} cells with knockdown of ZEB1 or/and ZEB2. (B) Protein expression of E-cadherin and vimentin in indicated CRA cells was tested by Western blot analysis. Immunofluorescence (C) and flow cytometry (D) analysis of E-cadherin and vimentin expression in Lovo\textsuperscript{miR-144-3p mimic} cells with overexpression of ZEB1 or/and ZEB2, and in HCT116\textsuperscript{miR-144-3p inhibitor} cells with knockdown of ZEB1 or/and ZEB2. (E) Representative IHC images of serial sections showed the expression of E-cadherin, vimentin, ZEB1, ZEB2 in NCMTs and CRATs with high miR-144-3p expression or low miR-144-3p expression determined by the cut-off value of qRT-PCR. *, P<0.05; **, P<0.01; ***, P < 0.001.
metastasis of renal cell carcinoma, gastric cancer, and breast cancer [18–20]. In this study we found that miR-144-3p regulated cell cytoskeleton, decreased vimentin expression while increased E-cadherin expression in CRA cells. These results indicate that miR-144-3p may suppress CRA metastasis by inhibiting EMT process.

ZEB1 and ZEB2 are EMT-associated transcription factors involved in tumor metastasis [40–42]. Based on miRNA target prediction algorithms, both ZEB1 and ZEB2 were predicted to contain binding site of miR-144-3p. We demonstrated that miR-144-3p bound 3'-UTR of ZEB1 and ZEB2, and inhibited their expression in CRA. In addition, ZEB1 and ZEB2 are overexpressed in CRA and are related with poor prognosis for CRA patients [43, 44]. In this study, the levels of miR-144-3p and ZEB1/2 were negatively correlated in CRAs, indicating that miR-144-3p may downregulate ZEB1 and ZEB2 in CRA. We further confirmed that overexpression of ZEB1 or ZEB2 alone could only partly recover inhibitory effects of miR-144-3p on CRA cell proliferation, migration and invasion, while overexpression of both ZEB1 and ZEB2 abrogated inhibitory effects of miR-144-3p on CRA cell proliferation, migration and invasion. Although miR-144 downregulated ZEB1 and ZEB2 in various types of cancers [44, 45], this is the first study to investigate the interaction of ZEB1/2 and miR-144 in CRA. By rescue experiments, we confirmed that ZEB1 and ZEB2 downregulation collaboratively mediated inhibitory effects of miR-144-3p on EMT in CRA. Therefore, our study systematically explored the role of miR-144-3p in CRA.

CONCLUSIONS

In summary, miR-144-3p was downregulated in CRA and its downregulation was significantly correlated to poor prognosis of CRA patients. Moreover, miR-144-3p inhibited CRA cell proliferation, invasion, and EMT process in vitro and suppressed CRA metastasis in vivo. Furthermore, we revealed the mechanism that miRNA-144-3p inhibited ZEB1 and ZEB2 expression to suppress CRA growth and metastasis. Therefore, our study suggested that miR-144-3p could be a therapeutic target and prognostic marker for CRA.

Abbreviations

CRC: colorectal cancer; CRA: colorectal adenocarcinoma; qRT-PCR: quantitative real-time polymerase chain reaction; CRAT: colorectal adenocarcinoma tissues; NCMT: noncancerous colorectal mucosa tissues; DFS: disease free survival; OS: and overall survival; EMT: epithelial-mesenchymal transition; IHC: Immunohistochemistry; IF: Immunofluorescence; ZEB1/2: zinc finger E-box binding homeobox 1/2.

AUTHOR CONTRIBUTIONS

Xiong Lei designed the experiments. Xiong Lei, Bo Tang, Zhixiang Huang, Cheng Tang, and Hua Dai performed experiments and analyzed data. Taiyuan Li, Xiong Lei, Cheng Tang, Benping Xiao, Hua Dai and Jianfeng Li provided patient samples and collected data. Xiong Lei wrote and revised the paper.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This study was supported by the National Natural Science Foundation of China (grant no. 81702922), National Health Commission Foundation of Jiang Xi, China (grant no. 20191016), key project of Natural Science Foundation of Jiangxi, China (grant no. 20192ACBL21043).

Editorial note

*This corresponding author has a verified history of publications using a personal email address for correspondence.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. https://doi.org/10.3322/caac.21492 PMID:30207593

2. Lei X, Deng L, Liu D, Liao S, Dai H, Li J, Rong J, Wang Z, Huang G, Tang C, Xu C, Xiao B, Li T. ARHGEF7 promotes metastasis of colorectal adenocarcinoma by regulating the motility of cancer cells. Int J Oncol. 2018; 53:1980–96. https://doi.org/10.3892/ijo.2018.4535 PMID:30132516

3. McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches. Curr Med Chem. 2017; 24:1537–57. https://doi.org/10.2174/0929867324666170111152436 PMID:28079003

4. Manfredi S, Lepage C, Hatem C, Coatmeur O, Fairev J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006; 244:254–59. https://doi.org/10.1097/01.sla.0000217629.94941.cf
5. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147:275–92. https://doi.org/10.1016/j.cell.2011.09.024 PMID: 22000009

6. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871–90. https://doi.org/10.1016/j.cell.2009.11.007 PMID: 19945376

7. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008; 14:818–29. https://doi.org/10.1016/j.devcel.2008.05.009 PMID: 18539112

8. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016; 166:21–45. https://doi.org/10.1016/j.cell.2016.06.028 PMID: 27368099

9. Vu T, Datta PK. Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers (Basel). 2017; 9:171. https://doi.org/10.3390/cancers9120171 PMID: 29258163

10. Díaz-López A, Moreno-Bueno G, Cano A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag Res. 2014; 6:205–16. https://doi.org/10.2147/CMAR.S38156 PMID: 24812525

11. Bonfrate L, Altomare DF, Di Lena M, Traviglio E, Rotelli MT, De Luca A, Portincasa P. MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. J Gastrointestin Liver Dis. 2013; 22:311–20. PMID: 24078989

12. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857–66. https://doi.org/10.1038/nrc1997 PMID: 17060945

13. Liu W, Lu Y, Zhang D, Shi L, Zu G, Yan H, Sun D. MicroRNA-708 inhibits the proliferation and chemoresistance of pancreatic cancer cells. Biocell. 2020; 44:73–80. https://doi.org/10.32604/biocell.2020.08613

14. Wu J, Zhao Y, Li F, Qiao B. MiR-144-3p: a novel tumor suppressor targeting MAPK6 in cervical cancer. J Physiol Biochem. 2019; 75:143–52. https://doi.org/10.1007/s13105-019-00681-9 PMID: 31016619

15. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs—the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009; 9:293–302. https://doi.org/10.1038/nrc2619 PMID: 19262572

16. Fei X, Hu W, Wang G, Su C, Huang X, Jiang Z. Effect of microRNA-143-3p- mediated CTNNB1 on the biological function of lung cancer cells. Biocell. 2020; 44:81–88. https://doi.org/10.32604/biocell.2020.08125

17. Cheng ZX, Song YX, Wang ZY, Wang Y, Dong Y. miR-144-3p serves as a tumor suppressor by targeting FZD7 and predicts the prognosis of human glioblastoma. Eur Rev Med Pharmacol Sci. 2017; 21:4079–86. PMID: 29028093

18. Liu F, Chen N, Xiao R, Wang W, Pan Z. miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochem Biophys Res Commun. 2016; 480:87–93. https://doi.org/10.1016/j.bbrc.2016.10.004 PMID: 27717821

19. Li B, Zhang S, Shen H, Li C. MicroRNA-144-3p suppresses gastric cancer progression by inhibiting epithelial-to-mesenchymal transition through targeting PBX3. Biochem Biophys Res Commun. 2017; 484:241–47. https://doi.org/10.1016/j.bbrc.2017.01.084 PMID: 2811340

20. Yu L, Yang Y, Hou J, Zhai C, Song Y, Zhang Z, Qiu L, Jia X. MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncol Rep. 2015; 34:1845–52. https://doi.org/10.3892/or.2015.4173 PMID: 26252024

21. Tan Y, Lin JJ, Yang X, Gou DM, Fu L, Li FR, Yu XF. A panel of three plasma microRNAs for colorectal cancer diagnosis. Cancer Epidemiol. 2019; 60:67–76. https://doi.org/10.1016/j.canep.2019.01.015 PMID: 30925282

22. Chang RM, Xiao S, Lei X, Yang H, Fang F, Yang LY. miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma. Clin Cancer Res. 2017; 23:2593–604. https://doi.org/10.1158/1078-0432.CCR-16-0851 PMID: 27827315

23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, and Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97:1180–84. https://doi.org/10.1093/jnci/dji237 PMID: 16106022

24. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Biol. 2019; 20:69–84. https://doi.org/10.1038/s41580-018-0080-4 PMID:30459476

25. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178–96. https://doi.org/10.1038/nrm3758 PMID:24556840

26. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015; 4:e05005. https://doi.org/10.7554/eLife.05005 PMID:26267216

27. Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019; 20:18. https://doi.org/10.1186/s13059-019-1629-z PMID:30670076

28. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, Chiew MY, Tai CS, Wei TY, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018; 46:D296–302. https://doi.org/10.1093/nar/gkx1067 PMID:29126174

29. Tokar T, Pastrello C, Rossos AE, Abovsky M, Hauschild AC, Tsay M, Lu R, Jurisica I. mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res. 2018; 46:D360–70. https://doi.org/10.1093/nar/gkx1144 PMID:29194489

30. Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review. Pathol Res Pract. 2015; 211:557–69. https://doi.org/10.1016/j.prp.2015.05.010 PMID:26092594

31. Ahmadiankia N, Khosravi A. Significance of epithelial-to-mesenchymal transition induction transcription factors in predicting distance metastasis and survival in patients with colorectal cancer: A systematic review and meta-analysis. J Res Med Sci. 2020; 25:60. https://doi.org/10.4103/jrsm.jrsm_174_19 PMID:33088297

32. Mooney SM, Jolly MK, Levine H, Kulkarni P. Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins. Asian J Androl. 2016; 18:704–10. https://doi.org/10.4103/1008-682X.183570 PMID:27427552

33. White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol. 2011; 8:75–84. https://doi.org/10.1038/nrclinonc.2010.173 PMID:21045789

34. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20:460–69. https://doi.org/10.1016/j.molmed.2014.06.005 PMID:25027972

35. Shirafkan N, Mansoori B, Mohammadi A, Shomali N, Ghasbi M, Baradaran B. MicroRNAs as novel biomarkers for colorectal cancer: New outlooks. Biomed Pharmacother. 2018; 97:1319–30. https://doi.org/10.1016/j.biopha.2017.11.046 PMID:29156521

36. Liu JL, Li J, Xu J, Xiao F, Cui PL, Qiao ZG, Chen XD, Tao WD, Zhang XL. MiR-144 Inhibits Tumor Growth and Metastasis in Osteosarcoma via Dual-suppressing RhoA/ROCK1 Signaling Pathway. Mol Pharmacol. 2019; 95:451–61. https://doi.org/10.1124/mol.118.114207 PMID:30674565

37. Liu CL, Wang WH, Sun YL, Zhuang HW, Xu M, Chen HF, Liu JX. MiR-144-3p inhibits the proliferation and metastasis of pediatric Wilms’ tumor cells by regulating Girdin. Eur Rev Med Pharmacol Sci. 2018; 22:7671–78. https://doi.org/10.26355/eurrev_201811_16384 PMID:30536309

38. Tao P, Wen H, Yang B, Zhang A, Wu X, Li Q. miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC. Exp Ther Med. 2018; 15:562–68. https://doi.org/10.3892/etm.2017.5392 PMID:29387205

39. Ma Y, Li W, Wang H. Roles of miRNA in the initiation and development of colorectal carcinoma. Curr Pharm Des. 2013; 19:1253–61. https://doi.org/10.2174/138161213804805784 PMID:23092337

40. Jolly MK, Cellà-Terrassa T. Dynamics of Phenotypic Heterogeneity Associated with EMT and Stemness during Cancer Progression. J Clin Med. 2019; 8:1542. https://doi.org/10.3390/jcm8101542 PMID:31557977

41. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 2008; 7:3112–18. https://doi.org/10.4161/cc.7.20.6851 PMID:18927505

42. Long ZH, Bai ZG, Song JN, Zheng Z, Li J, Zhang J, Cai J, Yao HW, Wang J, Yang YC, Yin J, Zhang ZT. miR-141 Inhibits Proliferation and Migration of Colorectal Cancer
43. Chen H, Lu W, Huang C, Ding K, Xia D, Wu Y, Cai M. Prognostic significance of ZEB1 and ZEB2 in digestive cancers: a cohort-based analysis and secondary analysis. Oncotarget. 2017; 8:31435–48. https://doi.org/10.18632/oncotarget.15634 PMID:28416756

44. Li MZ, Wang JJ, Yang SB, Li WF, Xiao LB, He YL, Song XM. ZEB2 promotes tumor metastasis and correlates with poor prognosis of human colorectal cancer. Am J Transl Res. 2017; 9:2838–51. PMID:28670373

45. Pan Y, Zhang J, Fu H, Shen L. miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. Onco Targets Ther. 2016; 9:6247–55. https://doi.org/10.2147/OTT.S103650 PMID:27785072
SUPPLEMENTARY MATERIALS

Cell lines

The normal colorectal mucosal cell line FHC, and colorectal adenocarcinoma (CRA) cell line SW480, SW620, HCT116, LoVo, HT-29 cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). Short tandem repeat (STR) DNA fingerprinting was used to authenticate all cell lines prior to commencement of the study. All cell lines were routinely cultured with RPMI-1640 (Gibco; Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), and maintained in a 5% CO₂ humidified incubator at 37°C.

qRT-PCR analysis

Total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc) according to the manufacturer's protocol. After determining the concentration, the RNA was then reverse transcribed to obtain cDNA using the universal cDNA synthesis kit (Toyobo, Osaka, Japan). qRT-PCR analysis was performed using the SYBR®-Green Realtime PCR Master Mix assay kit (Toyobo, Osaka, Japan). GAPDH and U6 were used as internal controls for gene mRNA and miRNA respectively. The primer sequences were as follows:

miR-144-3p: F: 5'-TACTGCATCAGGAACTGACTG GA-3'; R: 5'-GTGCAGGTTCCAGGTT-3'.

U6: F: 5'-GCTTCGGCAGACACATATAAAAT-3'; R: 5'-CGCTTCAGAATTTGCGTCAT-3'.

cadherin: F: 5'-CGAGAGCTACAGTGGCTACGG-3'; R: 5'-GGGTGTCAGGGGAAAAATAGG-3'.

Vimentin: F: 5'-AGTCCACTGAGTCCGGAGAC-3'; R: 5'-CATTTTCACGCATCTGGCTTCC-3'.

ZEB1: F: 5'-TTACACCTTTGTGATACACAGACC-3'; R: 5'-TTACGATTACACCCAGACTGC-3'.

ZEB2: F: 5'-GGAGACGGTCCAGCTAGTGT-3'; R: 5'-CCACTCCACCCTTCATTTC-3'.

GAPDH: F: 5'-GCACCGTCAAGGTGAGAAG-3'; R: 5'-TGGTGAAGACGCAGTGGA-3'.

The results were analyzed using 2-ΔΔCt or 2-ΔΔCt method to determine the relative expression level of corresponding genes.

Western blot analysis

Total proteins were extracted by RIPA lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China). The protein concentrations were measured according to BCA method (Beyotime Institute of Biotechnology). A total of 50 µg protein was subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto PVDF membranes (Millipore; Bedford, MA, USA). Then, the membranes were incubated with primary antibodies and subsequently incubated with the appropriate secondary antibodies (Cell Signaling Technology; Beverly, MA, USA). Bands were detected with enhanced chemiluminescence reagents (Thermo Fisher Scientific). β-actin (MilliporeSigma; St Louis, MO, USA) was used as a loading control. The primary antibodies used in this study were as follows: mouse anti-β-actin antibody (MilliporeSigma; St Louis, MO, USA), mouse anti-E-cadherin antibody (CST; Danvers, MA, USA), mouse anti-vimentin antibody (CST), rabbit anti-ZEB1 antibody (Affinity Biosciences, Jiangsu, China), rabbit anti-ZEB2 antibody (Affinity Biosciences).

Cell transfection

miR-144-3p mimic or inhibitor and their corresponding control sequences (RiboBio, Guangzhou, China) were transfected into the indicated CRA cells using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific Inc) following the manufacturer's protocol. After 48h transfection, the transfected cells were harvested and verified their efficiency for subsequent experiments. For transfection of ZEB1 and ZEB2 ORF for ZEB1 and ZEB2 overexpression or short hairpin RNA (shRNA) for ZEB1 and ZEB2 knockdown, the lentiviral vectors encoding ZEB1 and ZEB2 ORF or shRNA-ZEB1/2 were synthesized and purchased from GenePharma Co., Ltd (Shanghai, China). The empty vector was used as the negative control. The sequences of shRNAs for ZEB1 and ZEB2 knockdown were as follows: shRNA-ZEB1: 5'-CCUAGUCAGCCACCUUUATT-3'; shRNA-ZEB2: 5'-GUAUGACUAGGGCUA UUA-3'. Lentiviral vectors were transfected into cells in 6-well plates using Lipofectamine® 3000 (Invitrogen, Thermo Fisher Scientific Inc.) according the manufacturer's protocol. The efficiency of knockdown or overexpression of ZEB1 and ZEB2 was confirmed by qRT-PCR and western blot. The stably transfected cells were subjected to subsequent experiments.
Cell proliferation and colony formation assays

Methyl thiazolyl tetrazolium (MTT) assays and colony formation assays were used to determine CRA cell proliferation ability. For the MTT assays, 5 × 10^3 cells were seeded into each well of 96-well plates. 100 μl fresh medium containing 0.5 mg/ml MTT (MilliporeSigma) was added into each well and incubated at 37°C for 4 h. The absorbance was measured at 570 nm. For the colony formation assay, about 500 cells were seeded into 35-mm cell-culture dishes (Corning Incorporated; Corning, NY, USA) and cultured for 2 weeks. The number of colonies per dish was calculated following being stained with crystal violet (Beyotime Institute of Biotechnology, Jiangsu, China). Only positive colonies (diameter > 40μm) were calculated and compared. The experiments were repeated three times.

EdU proliferation assays

Cell proliferation was detected using the incorporation of 5-ethyl-2'-deoxyuridine (EdU) with the EdU Cell Proliferation Assay Kit (Ribobio, Guangzhou, China). Briefly, the indicated cells were seeded in 96-well plates and cultured in complete media under the condition of 5% CO₂, at 37°C. After incubation with 50 μM EdU for 4h, the cells were fixed, permeabilized and stained with EdU in order according to the manufacturer's protocol. Then the cell nuclei were stained with DAPI at a concentration of 1 μg/ml for 30 second. The typical images of the plates were taken using an inverted fluorescence microscope (Nikon Corporation, Tokyo, Japan). The experiments were repeated with three wells.

Transwell assay

Transwell migration and invasion assays were separately used to test CRA cell motility and invasion ability. Briefly, after pre-incubation with 10 μg/ml Mitomycin-C for 1 h to inhibit cell proliferation, about 1x10^5 cells in serum free medium were placed into the upper chamber of the insert. The upper chamber of the insert was coated with Matrigel (BD Biosciences; Franklin Lakes, NJ, USA) used for Transwell invasion assays, while the upper chamber of the insert without Matrigel used for Transwell migration assays. Following incubation for 24 h, the number of cells that adhered to the lower membrane of the inserts was calculated after stained with 0.1% crystal violet (Beyotime Institute of Biotechnology). For each group, the assays were repeated three times, and five random fields of view were selected for analysis.

Adhesion assay

The adhesive ability of the CRA cells was analyzed by cell-extracellular matrix (ECM) and cell-cell adhesion assays. For the cell-ECM adhesion assay, a 96-well plate was plated with fibronectin at 37°C for 60 min and washed twice with DMEM buffer supplied with 0.1% BSA (HyClone, GE Healthcare Life Sciences; Logan, UT, USA). The plates were blocked with DMEM buffer supplied with 0.5% BSA at 37°C in a 5% CO₂ incubator for 60 min. About 1 × 10⁴ cells (100 μl cells at a density of about 1x10⁵/ml) were added into each well of a 96-well plate (Costar; Corning Incorporated, Corning, NY, USA) and cultured at 37°C. Five wells for each group were determined at 60, 90 or 120 min. After remove of the non-adhesion cells, then 100 μl fresh medium containing 0.5 mg/ml MTT (MilliporeSigma) was added into each well and incubated at 37°C for 4 hours. The wells were then added 100 μl DMSO following remove of the medium and shaken at room temperature for 10 min. Finally, the absorbance was measured at 570 nm. For the cell-cell adhesion assay, sub-confluent (70-80%) cell layers were rinsed twice with Ca²⁺ and Mg²⁺-free PBS and separated by incubation in HBSS containing 1 mmol/L EDTA at 37°C for 20 min. And then, 100 μl single cells at density of about 1 × 10⁵/ml were added into a 96-well plate (Corning Costar Incorporated) with a fully confluent single cell layer, and cultured at 37°C for 0-120 min. The non-adhesion cells were collected from the wells, and counted using an inverted TE-2000S microscope (Nikon Corporation). The adhesion rate was determined by calculating representative aliquots from each well on a hemocytometer. The adhesion rate was calculated at 60, 90 or 120 min as follow: Nt/N₀ ×100%, where Nt is the number of non-adhesion cells at the incubation time t, and N₀ is the total number of cells added.

Immunofluorescence (IF)

The CRA cells were grown on the glass coverslips, and then fixed with 4% paraformaldehyde. After permeated in phosphate-buffered saline (PBS) with 0.2% Trion X-100, CRA cells were blocked for an hour with 1% bovine serum albumin (BSA), and then incubated with primary antibody overnight at 4°C. In the following day, the cells incubated with appropriate concentration of secondary antibody (Beyotime Institute of Biotechnology) and DAPI (Beyotime Institute of Biotechnology) separately. Images of the slides were captured using an inverted fluorescence microscope. Primary antibodies for E-cadherin, vimentin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Flow cytometry

CRA cells were seeded in 6-well plates and incubated for 24 h. Then monocytes were washed and incubated with E-cadherin, vimentin antibody (CST; Danvers, MA, USA) at a dilution of 1:10 in phosphate buffered saline (PBS)-bovine serum albumin (BSA) for 30 min at 4°C.
Cells were incubated with an isotype immunoglobulin G (IgG) antibody as control. Cells were filtered through a 70 μM cell strainer immediately prior to flow cytometry, which was carried out on a FACS caliber flow cytometer (BD Biosciences, San Jose, CA).

**Luciferase reporter assay**

Luciferase activity was assessed according to the Dual-Luciferase Reporter Assay protocol (Promega, Madison, WI, USA) using a Veritas™ 96-well Microplate Luminometer (Promega) with substrate dispenser (Promega). 293T cells infected with miR-144-3p mimic or control were seeded in 96-well plates with 70% confluence. 12 hours later, the cells were co-transfected with 50 ng pGL3-UTR and 10 ng pRLTK by using Lipofectamine LTX. After transfection 24 hours, firefly and Renilla luciferase activities were measured. The Renilla luciferase activities were used to normalize transfection efficiency.